| Bioactivity | Gap19 TFA, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 TFA inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 TFA is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 TFA has protective effects against myocardial[1][2]. | ||||||
| Invitro | Gap19 TFA (250 μM; for 30 min ) decreases mitochondrial potassium uptake[1]. Gap19 TFA (400 μM) inhibits unitary hemichannel currents in HeLa-Cx43 cells[2]. Gap19 TFA (100 μM) inhibits hemichannel unitary currents in ventricular cardiomyocytes[2]. Gap19 TFA (250 μM, 30 min) protects against myocardial ischemia/reperfusion injury in vitro and in vivo[2]. | ||||||
| Name | Gap19 TFA | ||||||
| Shortening | KQIEIKKFK | ||||||
| Formula | C57H97F3N14O15 | ||||||
| Molar Mass | 1275.46 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |